GlassScriptPhysician profile
Stephanie Oeswein
NPI 1376940569
$5,260.00
in general payments reported to CMS, 2019-2025
60 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $360 · 2022: $715 · 2023: $1,309 · 2024: $1,698 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,164 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,163.62 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $528.98 | 2022-2025 | |
| Incyte Corporation | $376.47 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $311.66 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $299.62 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $278.14 | 2021-2025 | Tagrisso, Enhertu, Lynparza |
| Abbvie INC. | $224.44 | 2023-2025 | |
| Pfizer INC. | $200.29 | 2022-2025 | |
| Amgen INC. | $194.97 | 2021-2024 | |
| Astellas Pharma US INC | $175.92 | 2022-2025 | Vyloy, Xospata, Padcev |
| Genentech USA, INC. | $157.48 | 2021-2025 | Venclexta, Polivy, Itovebi |
| Takeda Pharmaceuticals U.S.A., INC. | $157.45 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Genzyme Corporation | $156.45 | 2023-2025 | |
| Seagen INC. | $124.08 | 2022-2023 | Tukysa |
| Janssen Biotech, INC. | $120.10 | 2021-2024 | Rybrevant, Erleada, Balversa |
| Beigene USA, INC. | $110.00 | 2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $81.59 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $81.12 | 2021-2025 | Opdivo |
| Taiho Oncology, INC. | $81.02 | 2022-2025 | |
| Stemline Therapeutics INC. | $80.93 | 2024-2025 | Orserdu, Elzonris |
| Blueprint Medicines Corporation | $79.39 | 2022-2025 | Ayvakit |
| Lilly USA, LLC | $77.68 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $70.52 | 2022-2025 | |
| Gilead Sciences, INC. | $67.75 | 2022-2025 | Trodelvy |
| Sobi, INC | $66.86 | 2022-2024 | |
| Coherus Oncology, INC. | $64.56 | 2023-2024 | |
| Adc Therapeutics America, INC. | $62.77 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $58.62 | 2021-2025 | Onivyde |
| Array Biopharma INC | $48.82 | 2022-2024 | Mektovi, Braftovi, Lorbrena |
| Sun Pharmaceutical Industries INC. | $47.66 | 2023-2024 | Yonsa, Odomzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.12 | 2021-2023 | Gilotrif |
| Karyopharm Therapeutics INC. | $46.36 | 2023-2024 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $44.77 | 2022-2025 | |
| Mirati Therapeutics, INC. | $39.08 | 2023 | Krazati |
| Glaxosmithkline, LLC. | $38.85 | 2021-2025 | Blenrep |
| Kyowa Kirin, INC. | $38.70 | 2023-2025 | Poteligeo |
| Kite Pharma, INC. | $36.63 | 2021-2023 | |
| Celgene Corporation | $36.32 | 2024 | Reblozyl, Pomalyst |
| Alnylam Pharmaceuticals INC. | $36.22 | 2024 | Givlaari |
| Pharmaessentia USA Corporation | $35.13 | 2022-2023 | Besremi |
| Pharmacosmos Therapeutics INC. | $34.21 | 2023-2024 | Cosela, Monoferric |
| Iovance Biotherapeutics, INC. | $34.14 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $33.41 | 2022-2023 | Rezlidhia, Tavalisse |
| Novo Nordisk INC | $32.10 | 2023 | |
| Deciphera Pharmaceuticals INC. | $32.09 | 2025 | Romvimza, Qinlock |
| Lundbeck LLC | $30.41 | 2023 | Vyepti |
| Springworks Therapeutics, INC. | $30.28 | 2024 | Ogsiveo |
| Pharmacyclics LLC, An Abbvie Company | $29.11 | 2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $22.22 | 2023 | Libtayo |
| Genmab U.S., INC. | $20.81 | 2021 | |
| Tersera Therapeutics LLC | $19.54 | 2023 | Zoladex |
| Janssen Pharmaceuticals, INC | $18.69 | 2023 | Xarelto |
| Sumitomo Pharma America, INC. | $17.66 | 2023 | Orgovyx |
| Pharming Healthcare, INC. | $17.23 | 2023 | Ruconest |
| Foundation Medicine, INC. | $16.21 | 2023 | Foundationone Liquid Cdx |
| Legend Biotech USA INC. | $16.05 | 2025 | Carvykti |
| Novocure INC. | $15.39 | 2024 | Optune Lua (Novottf-200t) |
| Caris Mpi, INC. | $14.71 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $14.10 | 2025 | Sylvant |
| Apellis Pharmaceuticals, INC. | $13.71 | 2024 | Empaveli |
| Morphosys, US INC. | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Oeswein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.